Alnodesertib

Alnodesertib
Clinical data
Other names	GTPL13731; BDBM570448; ART-0380; IACS-030380
Identifiers
	IUPAC name 4-[4-[(cyclopropyl-methyl-oxo-λ6-sulfanylidene)amino]-6-[(3R)-3-methylmorpholin-4-yl]pyrimidin-2-yl]pyridin-2-amine;
CAS Number	2267316-76-5;
PubChem CID	145766632;
IUPHAR/BPS	13731;
ChemSpider	129644222;
ChEMBL	ChEMBL5505926;
Chemical and physical data
Formula	C18H24N6O2S
Molar mass	388.49 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H]1COCCN1C2=NC(=NC(=C2)N=[S@](=O)(C)C3CC3)C4=CC(=NC=C4)N;
	InChI InChI=InChI=1S/C18H24N6O2S/c1-12-11-26-8-7-24(12)17-10-16(23-27(2,25)14-3-4-14)21-18(22-17)13-5-6-20-15(19)9-13/h5-6,9-10,12,14H,3-4,7-8,11H2,1-2H3,(H2,19,20)/t12-,27+/m1/s1; Key:JHPDHYAMSPMBIF-MUDIAHQHSA-N;

Alnodesertib is an investigational new drug that is being developed by Artios Pharma for the treatment of solid tumours.^[1]^[2] It is an ataxia telangiectasia and Rad3 related (ATR) protein inhibitor.^[1]^[3]^[4]

Clinical trials

Alnodesertib is currently in clinical trials for solid tumors.^[5] Another study was terminated "not for reasons affecting the benefit-risk balance".^[6]

References

1 2 "Alnodesertib - Artios Pharma". AdisInsight. Springer Nature Switzerland AG.
↑ "WHO proposed international nonproprietary names list" (PDF). World Health Organization. Retrieved 3 July 2026.
↑ Qin S, An J, Qiao W, Zhichao X, Siyao T, Seo G, et al. (June 2026). "Resistance-centered pharmacology of DNA damage response-targeted therapy: Mechanisms, predictive biomarkers, and biomarker-guided adaptive treatment strategies in solid tumors". Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 201 119670. doi:10.1016/j.biopha.2026.119670. PMID 42314345.
↑ Kciuk M, Wanke K, Marciniak B, Kołat D, Aleksandrowicz M, Mujwar S, et al. (January 2026). "Targeting ATR-CHK1 and ATM-CHK2 Axes in Pancreatic Cancer-A Comprehensive Review of Literature". International Journal of Molecular Sciences. 27 (3): 1152. doi:10.3390/ijms27031152. PMC 12898043. PMID 41683580.
↑ Clinical trial number NCT04657068 NCT04657068 for "A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors" at ClinicalTrials.gov
↑ Clinical trial number NCT05798611 for "Study of ART0380 in Patients With Biologically Selected Solid Tumors" at ClinicalTrials.gov

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.

[AdisInsight-1] 1 2 "Alnodesertib - Artios Pharma". AdisInsight. Springer Nature Switzerland AG.

[INN1-2] "WHO proposed international nonproprietary names list" (PDF). World Health Organization. Retrieved 3 July 2026.

[Qin_2026-3] Qin S, An J, Qiao W, Zhichao X, Siyao T, Seo G, et al. (June 2026). "Resistance-centered pharmacology of DNA damage response-targeted therapy: Mechanisms, predictive biomarkers, and biomarker-guided adaptive treatment strategies in solid tumors". Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 201 119670. doi:10.1016/j.biopha.2026.119670. PMID 42314345.

[Kciuk_2026-4] Kciuk M, Wanke K, Marciniak B, Kołat D, Aleksandrowicz M, Mujwar S, et al. (January 2026). "Targeting ATR-CHK1 and ATM-CHK2 Axes in Pancreatic Cancer-A Comprehensive Review of Literature". International Journal of Molecular Sciences. 27 (3): 1152. doi:10.3390/ijms27031152. PMC 12898043. PMID 41683580.

[5] Clinical trial number NCT04657068 NCT04657068 for "A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors" at ClinicalTrials.gov

[6] Clinical trial number NCT05798611 for "Study of ART0380 in Patients With Biologically Selected Solid Tumors" at ClinicalTrials.gov

[1]

[2]

[3]

[4]

[5]

[6]